Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 2, 2009

Novartis to Kick Off R&D Alliance with Epistem with $4M

  • Epistem entered an R&D collaboration with Novartis to identify new drug targets and therapeutics across a variety of disease areas. Novartis will pay $4 million up front and provide research funding for two years.

    Epistem will also receive a license fee and up to $45 million in milestones for each target Novartis gains rights to. Additionally, Novartis will pay tiered royalties.

    The collaboration combines Epistem's stem cell expertise and drug discovery program with Novartis' insights into disease pathways and bioinformatics. Novartis has an option to exclusively license targets for development of biotherapeutic products.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »